Role of tachykinins in bronchoconstriction induced by intravenous administration of bradykinin in guinea-pigs

C. Kuroiwa*†, E. Umeno*‡, H. Nogami*‡, S. Kano*‡, T. Hirose*‡, S. Nishima*‡


ABSTRACT: To elucidate the role of tachykinins in bronchoconstriction induced by intravenous administration of bradykinin (Bk), we studied the effects of FK224, a neurokinin-1 (NK1) and neurokinin-2 (NK2) receptor antagonist, on the bronchoconstriction induced by intravenous (i.v.) administration of Bk (5–100 µg·kg⁻¹) in guinea-pigs.

Total pulmonary resistance (Rₔ) was measured using a pressure-volume sensitive body plethysmograph in anaesthetized artificially ventilated guinea-pigs pretreated with atropine (1 mg·kg⁻¹) and propranolol (1 mg·kg⁻¹).

In the control group, i.v. administration of Bk produced a dose-dependent increase in Rₔ. In animals pretreated with FK224, bronchoconstriction induced by higher doses of Bk (10, 50 and 100 µg·kg⁻¹) was significantly reduced, whilst the bronchoconstriction caused by lower doses of Bk (5 and 7.5 µg·kg⁻¹) was not. Pretreatment with a combination of FK224 and indomethacin markedly inhibited the bronchoconstriction induced by each dose of Bk compared with the groups pretreated with FK224 alone. Although pretreatment with indomethacin alone significantly reduced Rₔ at a high dose of Bk (50 µg·kg⁻¹), the reduction was significantly lower than that produced by a combination of FK224 and indomethacin.

These results suggest that intravenous administration of a high dose of bradykinin causes bronchoconstriction both by cyclo-oxygenase products and by release of tachykinins.

bronchoconstriction induced by intravenously administered bradykinin was not associated with activation of NK1 receptors. However, it is not known whether bradykinin-induced bronchoconstriction may involve activation of NK2 receptors rather than NK1 receptors.

The purpose of the present study was to determine whether intravenous administration of bradykinin causes bronchoconstriction by activation of NK2 receptors in guinea-pigs using FK224, a novel tachykinin receptor antagonist, which exhibits selectivity both for NK1 and NK2 receptors [19, 20].

Materials and methods

Anaesthesia and measurement of pulmonary resistance

Eighty five male Hartley outbred guinea-pigs (Kyudo Co., Saga, Japan) weighing 350–450 g were anaesthetized intraperitoneally with sodium pentobarbital (50 mg·kg⁻¹). All animals were then ventilated with a constant-volume ventilator (Rodent ventilator model 683; Harvard Apparatus, Millis, MA, USA) delivering a tidal volume of 8 mL·kg⁻¹ at a frequency of 60 breaths·min⁻¹ via a tracheal cannula. A polyethylene catheter was inserted into the left jugular vein for intravascular medications. The animals were then placed in a pressure-volume-sensitive body plethysmograph. Pulmonary resistance (RL) was measured according to the method of Sorkness et al. [21]. Briefly, changes in transpulmonary pressure were measured using a Gould P231D transducer (Gould Instruments, Cleveland, OH, USA) connected to the water-filled oesophageal cannula, and tidal airflow was measured with a pneumotachograph (Fleisch No. 0000; Fleisch, Lausanne, Switzerland) coupled to a Validyne MP45-16 differential pressure transducer (Validyne Corp., Northridge, CA, USA). Tidal volume was obtained via electronic integration of the flow signal (Pulmonary Mechanics Analyzer Model 6; Buxco Electronics, Sharon, CT, USA). RL signals of pressure and flow signals were monitored via a four-channel chart recorder (Model RTA-1200; Nihon Kohden, Tokyo), and were also used in an analog computer (Pulmonary Mechanics Analyzer Model 6; Buxco) to determine breath-by-breath values for tidal volume, frequency and resistance. RL was computed as average values for the entire breath, using a covariance method (Buxco Program 3).

Drugs

The following drugs were used in the experiments: pentobarbital sodium (Dainippon Pharmaceutical Co., Osaka, Japan), FK224 (Fujisawa Pharmaceutical Co., Osaka, Japan), dimethylsulphoxide, bradykinin and indomethacin (Sigma Chemical Co., St. Louis, MO, USA), atropine sulphate (Tanabe Seiyaku Co., Osaka, Japan), propranolol hydrochloride (Sumitomo Pharmaceuticals, Osaka, Japan). FK224 ([(N-[N²-[N-[N-[2',3'-didehydro-N-methyl-N-[N-[3-(2-pentylenephyl)]-propionyl]-l-threonyl]l-lysyl]-l-leucyl]-l-phenylalanyl-l-allo-threonyl]-l-asparaginyl-l-serine-y-lactone]) was prepared as a stock solution of 25 mg·mL⁻¹ in dimethylsulphoxide (DMSO).

Pretreatment with FK224 and indomethacin

All animals were pretreated with atropine (1 mg·kg⁻¹ i.v.) and propranolol (1 mg·kg⁻¹ i.v.) 5 min before Bk administration. Dose-response curves to intravenous administration of Bk (5, 7.5, 10, 50 or 100 µg·kg⁻¹) were then constructed with different pretreatments. Animals were divided into four groups: Group 1 was pretreated with DMSO (0.2 mL·kg⁻¹ i.v., "Control group": n=5 for each dose of Bk); Group 2 with FK224 (5 mg·kg⁻¹ i.v., "FK group": n=5 for each dose of Bk); and Group 3 with FK224 and indomethacin (5 mg·kg⁻¹ i.v. for each, "FK and indomethacin group": n=5 for each dose of Bk). In Group 4 animals, the same doses of indomethacin and DMSO were also administered before 5 and 50 µg·kg⁻¹ of Bk administration (5 mg·kg⁻¹ i.v. for indomethacin and 0.2 mL·kg⁻¹ i.v. for DMSO, "Indomethacin group", n=5 for each dose of Bk) to assess the effect of indomethacin alone on the bronchoconstriction induced by lower and higher doses of Bk. DMSO and FK224 were administered 10 min before and indomethacin 30 min before injection of Bk. The sequence of addition of drugs, time course and maximal response are shown in figure 1.

Statistical analysis

RL values are expressed as mean±SEM. The significance of differences was assessed by Student's unpaired t-test. As compared to control. On the other hand, pretreatment with a combination of indomethacin and FK224 produced inhibition at all doses. This is clearly illustrated in figure 2, which displays the maximal increase in RL. The Control group, the administration of Bk (5–100 µg·kg⁻¹) produced a dose-dependent increase in RL. Pretreatment with FK224 significantly attenuated the increase in RL induced by high doses (10, 50 or 100 µg·kg⁻¹) of bradykinin (p<0.05). Pretreatment with a combination of indomethacin and FK224 markedly inhibited bradykinin-induced bronchoconstriction compared with the FK group (p<0.01) at each dose of Bk. Figure 3 shows the effect of indomethacin on Bk-induced bronchoconstriction. Although the pretreatment
Fig. 1. – Time course of increase in pulmonary resistance ($R_L$) values after i.v. administration of bradykinin (5–100 µg·kg$^{-1}$) in guinea-pigs. All animals were pretreated with atropine (1 mg·kg$^{-1}$ i.v.) and propranolol (1 mg·kg$^{-1}$ i.v.). Animals pretreated with DMSO (Control group: 0.2 mL·kg$^{-1}$ i.v., n=5), FK224 (FK group: 5 mg·kg$^{-1}$ i.v., n=5), and FK224 and indomethacin (5 mg·kg$^{-1}$ i.v. for each, n=5). Data are expressed as mean±SEM. *: p<0.05 compared with the values of control group; **: p<0.01 compared with the values of FK group. –– : Control group; — : FK group; ——— : FK+indomethacin group. DMSO: dimethyl sulphoxide; Bk: bradykinin.
Dose of BK (50 µg·kg⁻¹) was administered (p<0.01). Significantly greater than by indomethacin alone when a high dose of BK in vivo markedly inhibited the bronchoconstriction by cyclo-oxygenase products. FK224, a novel tachykinin receptor antagonist (selective both for neukin-1 and neukin-2 receptors), significantly attenuated the bronchoconstriction induced by intravenous administrations of higher doses (10, 50 or 100 µg·kg⁻¹) of BK in anaesthetized, mechanically-ventilated guinea-pigs. However, the bronchoconstriction induced by lower doses (5 or 7.5 µg·kg⁻¹) of BK was not affected. In addition, although pretreatment with indomethacin alone significantly reduced bronchoconstriction by a high dose of BK (50 µg·kg⁻¹), pretreatment with both FK224 and indomethacin markedly inhibited the bronchoconstriction.

There have been several studies concerning the effects of BK on airways in vivo. Some have shown that the direct administration of BK into the airway lumen may cause bronchoconstriction through cholinergic mechanisms [9], or a direct effect on the smooth muscle [22]. Airway oedema induced by sub or the release of tachykinins from C-fibres [17, 23]. Although intravenous administration of BK also induced bronchoconstriction by cholinergic mechanisms [24] and by a direct effect on the smooth muscle [25, 26], other studies have shown that it caused the release of cyclo-oxygenase products [17, 27]. In the present study, cholinergic mechanisms were not contributing to the response because all animals were pretreated with atropine.

However, there are no studies showing that tachykinins contribute to the bronchoconstriction induced by intravenous administration of bradykinin. A previous study with capsaicin pretreatment showed that tachykinins did not appear to play a role in bronchoconstriction induced by intravenously administered bradykinin [17]. The study with CP-96,345, a neukin-1 receptor antagonist, showed that bronchoconstriction induced by i.v. BK (15 nmol·kg⁻¹, i.e. about 15 µg·kg⁻¹) was not mediated by activation of the neukin-1 receptor [18]. Possible reasons for the different findings between the present study and previous studies might be due to the method of investigation. Instead of using capsaicin for desensitization of C-fibres as in the previous study, we used FK224, a novel tachykinin receptor antagonist. Capsaicin releases several neuropeptides (neuropeptide Y, vasoactive intestinal polypeptide, peptide histidine isoleucine, substance P, neukin-1, calcitonin-gene-related peptide, galamin) in the respiratory tree [28], which could affect bronchoconstriction and, therefore, the results of the experiment. To clarify the role of tachykinins more precisely, we used FK224 because it exhibits a dual inhibitory effect on neukin-1 and neukin-2 receptors [19, 20]. Neukin-1 receptors have a preferential affinity for substance P and lesser affinity for other tachykinins, such as neukin-1 A [29]; and neukin-2 receptors have a preferential affinity for neukin-1 A. FK224 inhibits bronchoconstriction induced by substance P or neukin-1 A, but it does not affect contraction mediated by histamine and acetylcholine in guinea-pig in vitro and in vivo [19, 20]. Airway oedema induced by substance P and neukin-1 A is also reduced by FK224.
The contractile response to neurokinin A and substance P was not affected by atropine or indomethacin [30]. Moreover, ICHINOSE et al. [17] reported that FK224 inhibited bronchoconstriction induced by inhalation of Bk in asthmatic patients and suggested that tachykinins released from the airway sensory nerves are involved in response to inhaled Bk. Therefore, our results suggest that higher concentrations of intravenously administered Bk induce bronchoconstriction by escaping from degradation by pulmonary endothelial cells and, consequently, release tachykinins, such as substance P and neurokinin A. The guinea-pig trachea contains receptors for neurokinin A, a potent stimulant of airway smooth muscle [31], and for substance P, which induces protein extravasation in the tracheal mucosa [32] as well as bronchoconstriction [18]. Thus, neurokinin A, which may be released predominantly by a high dose of intravenously administered Bk may induce bronchoconstriction. It is also possible that microvascular leakage could contribute to airway narrowing by the release of substance P. However, our data shows that higher concentrations of intravenously administered Bk induce bronchoconstriction induced by higher doses of Bk in the present study. To clarify the involvement of neurokinin-2 receptors precisely, further studies with a specific neurokinin-2 receptor antagonist will be needed.

As it has been reported that allergens increase bronchovascular permeability in the airways of human subjects with allergic asthma [7] and that asthmatic patients have an elevated concentration of kinin in their plasma [6], it seems likely that a concentration of Bk high enough to cause bronchoconstriction may gain access to airway C-fibres by diffusing from the plasma.

The present results are consistent with previous reports, which showed that low i.v. doses of Bk induced bronchoconstriction largely through the release of cyclooxygenase products. However, our data shows that higher doses of i.v. Bk can induce bronchoconstriction not only via cyclooxygenase products but also via tachykinin release.

In conclusion, high doses of intravenously administered bradykinin cause bronchoconstriction through the release of tachykinins and cyclo-oxygenase products. These results suggest the importance of a high concentration of plasma bradykinin in C-fibre stimulation in the pathogenesis of severe asthma attacks.

References


